William Blair analyst Matt Larew has maintained their bullish stance on ATR stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Larew has given his Buy rating due to a combination of factors that highlight AptarGroup’s strategic focus and financial performance. The company has demonstrated a significant shift towards becoming more pharma-centric, which is evident from its strong growth in the pharma segment. This segment now accounts for a substantial portion of the company’s revenue and EBITDA, showcasing its importance in AptarGroup’s overall business strategy.
Despite some challenges in the beauty and closures segments, AptarGroup has managed to achieve impressive profitability improvements. The company’s EBITDA margin has expanded significantly, and it is on track to reach the higher end of its margin targets. This focus on profitability, along with the continued emphasis on high-margin pharma products, supports the positive outlook for AptarGroup’s financial future, justifying the Buy rating.
In another report released yesterday, Raymond James also maintained a Buy rating on the stock with a $172.00 price target.